Page 2 - John Quisel News Today

WATERTOWN, Mass., Dec. 20, 2023 -- Disc Medicine, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients...

Substantial, dose-dependent reductions in serum hepcidin and increases in serum iron Hematologic response demonstrated by increased hemoglobin levels and reduction in transfusion burdenDISC-0974 was...

Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension , today announced...

The FDA has granted Fast Track designation to MWTX-003 (DISC-3405) for the treatment of patients with polycythemia vera.

The FDA has granted fast track designation to MWTX-003 (DISC-3405) for the treatment of patients with polycythemia vera.

The FDA has granted fast track designation to the investigational, anti-TMPRSS6 monoclonal antibody, MWTX-003 (DISC-3405), for use in the treatment of patients with polycythemia vera, according to an announcement from Disc Medicine, Inc.1

The FDA has granted Fast Track designation to MWTX-003 (DISC-3405) for the treatment of patients with polycythemia vera.

By Denny Jacob Disc Medicine's MWTX-003, a treatment for patients with polycythemia vera, was granted fast track designation by the U.S. Food and Drug...

By Denny Jacob Disc Medicines MWTX-003, a treatment for patients with polycythemia vera, was granted fast track designation by the U.S. Food and Drug Administration. Chief Executive John...

Disc Medicine, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic... | June 9, 2023